Last week, Medtronic announced the intent to separate its diabetes business into a new standalone company. The new company, which remains unnamed, is expected to launch within 18 months.

Medtronic reported a fourth quarter global revenue of nearly $9 billion on Wednesday, totaling more than $33.5 billion globally for fiscal year 2025.

Under Medtronic’s plan, the new unnamed company will also be publicly traded, Medtronic said. The diabetes business generated nearly $2.8 billion in sales in its most recent fiscal year, ...

(Reuters) -Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and ...

Medtronic said Wednesday that it plans to spin off its diabetes business in the next 18 months, creating a new diabetes technology company that can offer customers both insulin pumps and ...

Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 ...

A Micra AV pacemaker is on display. (Photo by Tang Yanjun/China News Service via Getty Images) Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last ...

Medtronic in 2015 acquired the brand’s parent, Covidien, for $49.9 billion. Du, the former Medtronic ventilation executive, is now the CEO of ventilator maker Nihon Kohden OrangeMed.

Medtronic shares slumped Tuesday after the medical device maker missed sales forecasts. The revenue miss came as sales of its stapling and blood oxygen management products slowed.

When Geoff Martha, chairman and CEO of Medtronic, took over the medical device maker’s Restorative Therapies Group in 2015, the company faced a tough decision.

Looking forward, Medtronic expects its organic sales to rise between 4.75% and 5%, and its adjusted earnings to be in the range of $5.44 and $5.50 in fiscal 2025. What Does This Mean For MDT Stock?

Medtronic said Friday that the U.S. Food and Drug Administration has approved a new spinal-cord implant that relieves chronic pain, a bid to expand into a patient population that relies heavily on ...